As the year progressed, the overall robust capabilities of the pharmacy industry and FDA regulators allowed drug development to remain at near-normal levels. (Image: Shutterstock)
Despite concerns about the effect of COVID-19 on the FDA's work in approving new pharmaceutical treatments, 2020 did not see a major drop-off in approvals, according to a new report from OptumRx.
OptumRx, a pharmacy benefits manager owned by UnitedHealth Group, recently released its OptumRx Drug Pipeline Insights Report. In addition to reporting on the general pace of approval of new drugs, it highlighted five notable drugs being reviewed by the FDA and their possible impact on the market in 2021.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
